What Is the Fair Value of UnitedHealth Group (UNH) Stock? Intrinsic Value Analysis

Quick Answer

As of July 2026, UnitedHealth Group (UNH) is fairly valued to slightly undervalued, depending on the valuation model applied. Following a robust second-quarter earnings report that saw the company raise its full-year 2026 guidance, the stock is trading around $424 per share.

Our blended intrinsic value analysis—incorporating Discounted Cash Flow (DCF), P/E multiples, PEG ratios, EV/EBITDA, and the Dividend Discount Model (DDM)—suggests a fair value range between $395 and $475 per share. While conservative earnings-based DCF models suggest the stock is fully priced, free cash flow models and forward-looking multiple analyses indicate upside potential. Notably, Morningstar recently upgraded its fair value estimate for UNH to $475 UnitedHealth Earnings: Strength Across the Board Boosts 2026 Outlook | Morningstar, reflecting strong margin expansion and exceptional cash generation.

Current Stock Price & Valuation

UnitedHealth Group continues to dominate the healthcare sector. In mid-July 2026, UNH reported Q2 revenue of $112 billion, beating consensus estimates, alongside a massive 56% adjusted EPS growth to $6.38 UnitedHealth Earnings: Strength Across the Board Boosts 2026 Outlook | Morningstar.

Here is a snapshot of UNH's market positioning as of late July 2026:

The market reacted positively to the Q2 2026 earnings, sending shares up roughly 5% as the company demonstrated excellent cost control, highlighted by a medical cost ratio (MCR) decline to 86.7% from 89.4% a year prior UnitedHealth Earnings: Strength Across the Board Boosts 2026 Outlook | Morningstar.

Detailed Analysis

To determine the true intrinsic value of UNH, we must look beyond the headline price and apply five distinct valuation methodologies.

1. Discounted Cash Flow (DCF) Analysis

DCF analysis values a company based on the present value of its future cash flows. We can look at this through two lenses: Earnings and Free Cash Flow (FCF).

Earnings-Based DCF:

Free Cash Flow (FCF) DCF: Because UNH is a cash-generating machine, FCF often paints a more accurate picture. Using a base FCF of ~$18.5 billion to $26.5 billion, an 8% growth rate, a 9% discount rate, and a 3.5% terminal rate, the FCF-based intrinsic value lands at $446.00 per share UnitedHealth Group (UNH) Fair Value Analysis (2026). This implies the stock is slightly undervalued at current levels.

2. P/E Multiple Analysis

Historically, UNH has commanded a premium valuation due to its wide economic moat and predictable growth.

3. PEG Ratio Analysis

The Price/Earnings-to-Growth (PEG) ratio helps contextualize the P/E ratio against the company's growth rate.

4. EV/EBITDA Valuation

Enterprise Value to EBITDA is crucial for assessing UNH without the distortion of capital structure.

5. Dividend Discount Model (DDM)

For income-focused investors, the DDM values the stock based on future dividend payouts.

Bull Case

The bullish argument for UNH in July 2026 centers on its exceptional operational efficiency. In Q2 2026, the company drove its medical cost ratio down to 86.7%, a significant improvement from 89.4% in the prior year UnitedHealth Earnings: Strength Across the Board Boosts 2026 Outlook | Morningstar. This margin expansion allowed management to raise 2026 operating cash flow guidance to a staggering $24 billion and increase share repurchases to at least $5 billion UnitedHealth Earnings: Strength Across the Board Boosts 2026 Outlook | Morningstar. Analysts at Morningstar raised their fair value estimate by 11% to $475 per share, citing these robust cash flows UnitedHealth Earnings: Strength Across the Board Boosts 2026 Outlook | Morningstar.

Bear Case

The bearish perspective relies heavily on conservative earnings-based DCF models. If we apply a strict 11% discount rate to UNH's EPS growth, the intrinsic value drops to $323.72, implying a -30% margin of safety UNH DCF Analysis: Intrinsic Value $324 vs Price $421. Furthermore, UNH operates in a highly regulated environment. Any unexpected shifts in Medicare Advantage reimbursement rates or broader healthcare policy could compress margins and slow the 13.2% projected long-term growth rate.

Key Metrics Summary

MetricJuly 2026 ValueImplication
Stock Price$424.62Baseline
Forward P/E19.5xModest premium, but below historical highs
PEG Ratio1.47Fairly valued relative to growth
Dividend Yield~2.1%Reliable income generation
2026 EPS Guidance$19.50 - $20.00Strong upward revision
Morningstar Fair Value$475.00Undervalued
FCF DCF Fair Value$446.00Undervalued

Frequently Asked Questions

Is UNH stock a buy, sell, or hold in July 2026?

Based on the convergence of multiple valuation models, UNH is a strong hold for current investors and a cautious buy for long-term investors. The stock is trading slightly below its blended fair value of ~$440, offering a modest margin of safety alongside reliable dividend growth.

Why did UNH stock rise in July 2026?

UNH shares rose approximately 5% in mid-July 2026 following a stellar Q2 earnings report. The company reported $112 billion in revenue, posted 56% adjusted EPS growth, and raised its full-year 2026 EPS guidance to $19.50-$20.00 UnitedHealth Earnings: Strength Across the Board Boosts 2026 Outlook | Morningstar.

What is UNH's dividend yield and is it safe?

UNH currently offers a dividend yield of approximately 2.1%, paying out $9.28 annually per share UnitedHealth Group (UNH) Fair Value Analysis (2026). Given the company's projected $24 billion in operating cash flow for 2026 UnitedHealth Earnings: Strength Across the Board Boosts 2026 Outlook | Morningstar, the dividend is exceptionally safe and has ample room for continued high-single-digit annual growth.

How does UNH's medical cost ratio (MCR) impact its valuation?

The MCR measures the percentage of premium revenues spent on clinical services. A lower MCR means higher profitability. In Q2 2026, UNH reduced its MCR to 86.7% from 89.4% UnitedHealth Earnings: Strength Across the Board Boosts 2026 Outlook | Morningstar. This 270-basis-point improvement directly translates to billions in free cash flow, which is why cash-flow-based valuation models have recently adjusted upward.

Final Verdict

After running UnitedHealth Group through five distinct valuation methodologies, the data points to a clear conclusion: UNH is fairly valued to slightly undervalued.

While a strict, high-discount-rate earnings DCF model suggests the stock is overpriced at $424, this model ignores the reality of UNH's massive free cash flow generation. When we look at the Free Cash Flow DCF ($446), the Dividend Discount Model ($442), and historical P/E multiples ($434), a consensus fair value emerges in the $440 to $450 range.

With management raising 2026 guidance and executing brilliantly on cost controls, UNH remains a premier, wide-moat compounder. Investors buying at current levels are paying a fair price for one of the highest-quality businesses in the global healthcare sector.

Ready to Analyze Your Next Investment?

Get a free AI-powered fair value analysis on any stock. See intrinsic value, margin of safety, and institutional-grade risk metrics in seconds. No credit card required.

Want full access to our institutional research tools? Explore Invest Daily Pro.

Put This Into Practice

You're reading about dividend safety. But is YOUR dividend actually safe?

Our AI analyzes payout ratio trends, free cash flow coverage, balance sheet risk, and dividend growth history to give every stock a Fortress Score from 0–100.

Watch: Related Videos

from Invest Daily
Watch: I Built an AI That Values Any Stock in 30 Seconds (Full Demo)
YouTube
Watch: $3 TRILLION Gone in One Day… What Happens to Stocks This Week?
YouTube

Get This Analysis in Your Inbox Every Morning

Get our daily market briefing with institutional-grade analysis, key developments, and actionable strategy - delivered before the opening bell.